BrightPath Biotherapeutics Co., Ltd. announced a private placement of 105,000 15th stock acquisition rights for proceeds of ¥1,127,175,000 and 1st unsecured corporate bonds for proceeds of ¥300,000,000 for aggregate proceeds of ¥1,427,175,000 on January 14, 2022 . The transaction included participation from Macquarie Bank Limited, Investment Arm. The potential shares from the issuance of stock acquisition rights will be 10,500,000 shares.

The initial exercise price of stock acquisition rights ¥107 for a period from February 2, 2022 to February 3, 2025. The transaction will happen through third party allocation. The company will incur issuance expenses with respect to the transaction including attorney's fees, price calculation costs, registration-related costs, etc.

The transaction is expected to close February 1, 2022. The transaction has been approved at board of directors' meeting of the company. The company paid ¥20,000,000 as as issue expenses in the transaction.

The bonds issued are redeemable with an annual Interest rate of 1%. The bonds are issued at an issue price of ¥100 per bond ¥100 face value. The bonds are redeemable for price of ¥100 per bond ¥100 face value.